一种新的甲基化特征预测胶质母细胞瘤的极端长期生存
研究对53例未治疗胶质母细胞瘤样本(12例极端长期生存者与41例中位生存者)进行DNA甲基化分析,检测865859个CpG位点,发现67个差异甲基化位点和5个差异甲基化区域,涉及干扰素β信号减弱、MAPK信号和NTRK信号通路,并用癌症基因组图谱数据库验证。
要点
- 未治疗胶质母细胞瘤样本中已存在与生存相关的基线DNA甲基化差异。
- 鉴定出67个差异甲基化位点和5个差异甲基化区域,涉及干扰素β、MAPK和NTRK信号通路。
- 这些甲基化差异可能部分解释胶质母细胞瘤预后的内在异质性。
核心结论
- 未治疗胶质母细胞瘤样本中已存在的基线DNA甲基化差异属于与肿瘤生存相关的基因和通路,可能部分解释决定胶质母细胞瘤患者预后的内在异质性。
研究设计与样本
- 收集53例未治疗胶质母细胞瘤样本进行DNA甲基化分析,包括12例极端长期生存者和41例中位生存者。
- 检测865859个CpG位点,分析两组间的差异甲基化位点和差异甲基化区域。
- 使用基因本体和通路功能注释识别相关生物学过程,并用癌症基因组图谱数据库验证发现。
主要发现
- 鉴定出67个差异甲基化位点和5个差异甲基化区域,关联基因和通路包括干扰素β信号减弱、MAPK信号和NTRK信号。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) is the most common malignant primary brain tumor with a dismal prognosis of less than 2 years under maximal therapy. Despite the poor prognosis, small fractions of GBM patients seem to have a markedly longer survival than the vast majority of patients. Recently discovered intertumoral heterogeneity is thought to be responsible for this peculiarity, although the exact underlying mechanisms remain largely unknown. Here, we investigated the epigenetic contribution to survival. METHODS: GBM treatment-naïve samples from 53 patients, consisting of 12 extremely long-term survivors (eLTS) patients and 41 median-term survivors (MTS) patients, were collected for DNA methylation analysis. 865 859 CpG sites were examined and processed for detection of differentially methylated CpG positions (DMP) and regions (DMR) between both survival groups. Gene Ontology (GO) and pathway functional annotations were used to identify associated biological processes. Verification of these findings was done using The Cancer Genome Atlas (TCGA) database. RESULTS: We identified 67 DMPs and 5 DMRs that were associated with genes and pathways - namely reduced interferon beta signaling, in MAPK signaling and in NTRK signaling - which play a role in survival in GBM. CONCLUSION: In conclusion, baseline DNA methylation differences already present in treatment-naïve GBM samples are part of genes and pathways that play a role in the survival of these tumor types and therefore may explain part of the intrinsic heterogeneity that determines prognosis in GBM patients.
引用
- Decraene B, Coppens G, Spans L, et al. A novel methylation signature predicts extreme long-term survival in glioblastoma. J Neurooncol. 2024. PMID: 38898218. doi:10.1007/s11060-024-04741-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。